Plain-English translation of NCT05573126 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is investigating a new medication called to see if it can help women with advanced or metastatic breast cancer that has specific characteristics (hormone-receptor positive and HER-2 negative). Researchers are testing the medication both on its own and combined with standard cancer treatments to find the best dose and understand how safe and effective it is.
Many women with hormone-receptor positive breast cancer develop resistance to current hormone therapies over time. This trial is exploring whether this medication could offer a new treatment option for women whose cancer has progressed despite previous treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will take the medication regularly and visit the study site for safety monitoring, blood tests, and imaging scans to track how your cancer responds. The trial has different treatment modules — some patients receive the new medication alone, while others receive it combined with one of several standard cancer drugs. Your involvement will span months as researchers carefully monitor your tolerability, side effects, and how well the treatment is working.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States